Company profile
Helixmith Co., Ltd.
084990 · Korea Exchange (KOSDAQ) (Publicly listed South Korean biotech (KOSDAQ:084990), formerly named ViroMed Co., Ltd. until its 2019 rename; developer of Engensis (VM202) gene therapy in diabetic peripheral neuropathy trials. Not on the roster. Sources: https://clinicaltrials.gov/study/NCT01475786 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://en.wikipedia.org/wiki/Helixmith ; https://stockanalysis.com/quote/kosdaq/084990/company/ Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Helixmith Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Beperminogene perplasmid (HGF plasmid)(Collategene) | Phase 3 | Undisclosed / early pipeline · Hepatocyte growth factor (HGF)Gene therapy / editing | Atherosclerotic Cardiovascular Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.